obesity1 min read
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market.
By Xinmei ShenSouth China Morning Post Tech

Read the full story
Originally published by South China Morning Post Tech on Nov 13, 2026.
Comments
Sign in to join the discussion.